HLB falls to the intraday lower limit amid an FDA request for supplementary materials in 7 month 10 day
HLB fell to the intraday lower limit after receiving a request from the U.S. FDA on 7 month 10 day to supplement clinical data for a new liver cancer drug. During the same period, news emerged of a 15% cut in Emart's target price, 83% concentration of trading value including leverage, an increased target price for Samsung SDS, and attention on KT&G's interim dividend.
HLB disclosed that it had received a request from the U.S. Food and Drug Administration (FDA) on 7 month 10 day to supplement clinical data related to a new liver cancer drug. Following the news, HLB's share price fell to the intraday lower limit.
The specific item in the request was identified in the disclosure as 'supplementary clinical data.' The disclosure did not include the company's schedule for additional submission or detailed response plan.
Emart was reported to have lowered its target price by 15% to reflect weak Starbucks sales and other factors. The adjustment reflected changes in earnings forecasts and sales expectations.
Meanwhile, in the stock market, leveraged products combined account for a share of trading value along with some individual stocks,83%. Concentration of trading around specific stocks was confirmed.
Samsung SDS announced that securities firms had raised their target prices as its AI data center business became more visible. The result reflected the alignment between the company’s business explanations and target-price revisions by the securities industry.
Kiwoom Securities highlighted KT&G’s interim dividend and shareholder-return policy and set a target price of22ten-thousand won. The possibility of an interim dividend was cited as an investment point.
These reports triggered price movements centered on individual issues in the domestic market from7 month 9~10 day. Each company’s official disclosures and securities-firm reports were reflected in intraday trading.